McKesson and Aetion to combine RWE platform, EHR data

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: McKesson, Aetion, RWE, Real world evidence

Aetion and McKesson today announced a strategic collaboration to advance the use of real world evidence in cancer research – offering joint solutions to support the FDA’s demonstration project and commercial customers.

As per the agreement, the companies will combine Aetion’s real world evidence (RWE) platform with data from McKesson’s iKnowMedSM oncology electronic health record (EHR) system.

Initially accessible to the researchers at Brigham and Women’s Hospital leading the US Food and Drug Administration (FDA) demonstration project, RCT DUPLICATE, the solutions will be available for commercial use, soon, an Aetion spokesperson told us.

“The joint solutions offered by McKesson and Aetion allow users to conduct regulatory-grade studies in major cancers and accelerate time to insight on oncology data,” ​they added.

According to the company, the biopharma industry invested $50bn to support oncology research in 2018 – and only saw an estimated 3% probability of success for any one product. In a bid to reduce the time and cost of drug development, the industry has increasingly been looking to RWE.

As the spokesperson outlined, the joint solutions to be offered by Aeiton and McKesson will enable researchers “to develop evidence for synthetic control arm and label expansion studies, to fulfill post-marketing safety requirements, and to assess the economic impact of treatments.”

While this is the companies’ first partnership, McKesson Ventures earlier this year participated in Aetion’s Series B funding round​.

Additionally, the companies also are part of the Friends of Cancer Research Real-World Evidence pilot project, which recently demonstrated​ the ability to extract several real-world endpoints from various datasets.

Last month, Aetion also announced​ that former FDA Commissioner Scott Gottlieb joined its board of directors to help to advance the use of RWE in drug development and commercialization.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars